Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Moleculin Biotech Inc buy melinda

Start price
€11.01
27.06.17 / 50%
Target price
€16.24
27.06.17
Performance (%)
1.28%
End price
€11.15
27.06.17
Summary
This prediction ended on 27.06.17 with a price of €11.15. The BUY prediction by melinda finished with a performance of 1.28%. melinda has 50% into this prediction

Moleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.

Performance without dividends (%)
Name 1w 1m 1y 3y
Moleculin Biotech Inc - - -53.933% -87.651%
iShares Core DAX® 1.883% 5.122% 21.667% 22.437%
iShares Nasdaq 100 0.125% 2.574% 45.951% 55.507%
iShares Nikkei 225® -0.201% 4.341% 28.806% 9.945%
iShares S&P 500 0.728% 4.141% 34.630% 50.086%

Comments by melinda for this prediction

In the thread Moleculin Biotech Inc diskutieren
Prediction Buy
Perf. (%) 1.28%
Target price 2.706
Change
Ends at 27.06.17

Biotech



Moleculin ad wissenschaftliche Unterstützung für Forschungsanstrengungen an der Mayo Clinic

HOUSTON, TX - (MARKET - 26. Juni 2017) - Moleculin Biotech, Inc. (NASDAQ: MBRX ) ( "Moleculin" oder das "Unternehmen"), ein vorklinischen pharmazeutischen Unternehmen , das sich auf die Entwicklung von Kandidaten für Krebsmedikamente, einige basierte auf Lizenzvereinbarungen mit der Universität of Texas System im Namen des MD Anderson Cancer Center, gab heute bekannt , dass es eine Vereinbarung mit einem Arzt an der Mayo Clinic erreichte am Moleküle WP1066 zusätzliche Forschung zu ermöglichen , Moleculin für die mögliche Behandlung einer seltenen Form von pädiatrischen Hirntumor.



Prediction Buy
Perf. (%) 1.28%
Target price 2.706
Change
Ends at 27.06.17

(Vom Mitglied beendet)

Stopped prediction by melinda for Moleculin Biotech Inc

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€5.97
15.07.20
€12.00
04.11.21
-62.48%
05.11.21

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€7.04
21.04.19
€8.12
22.04.19
13.85%
22.04.19

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€9.42
30.08.18
€14.61
23.01.19
-22.76%
23.01.19

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€11.15
28.02.18
€15.15
28.08.18
-17.48%
28.08.18

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€21.30
29.06.17
€42.00
19.12.17
-52.11%
19.12.17

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€19.21
29.06.17
€37.88
19.12.17
-52.11%
19.12.17

buy
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€5.68
22.06.17
€10.82
27.06.17
104.76%
27.06.17